INTRODUCTIONAntithrombotic therapy plays an essential role in the prevention of thrombotic complications during percutaneous coronary intervention (PCI) . The benefits of antithrombotic agents must be weighed against their potential risk of hemorrhagic complications, especially in complex PCI and patients with high risk of bleeding . Unfractionated heparin (UFH) and bivalirudin have been used most commonly for anticoagulation in PCI . Bivalirudin, a synthetic reversible direct thrombin inhibitor, can selectively block clot‐bound thrombin, potentially achieving a more potent and more predictable anticoagulant response than UFH . Numerous trials have consistently shown that bivalirudin could reduce bleeding complications compared with UFH . Therefore, bivalirudin appears to be a suitable alternative for anticoagulation in PCI. However, the safety and efficacy of bivalirudin in complex PCI procedure like chronic total occlusion (CTO) lesions are still uncertain.CTO is encountered in 15–30% of patients undergoing diagnostic coronary angiography . Compared to patients without CTO, CTO patients have more comorbidities, more extensive CAD and are more frequently referred for bypass surgery . Successful CTO PCI has been demonstrated to improve quality of life and left ventricular function, and reduce ischemia or the need for subsequent bypass surgery . However, CTO recanalization remains one of the most
Catheterization and Cardiovascular Interventions – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud